Lupin Tells Rakesh Jhunjhunwala In An Interaction

Rakesh Jhunjhunwala Tips & Portfolio

The management of Lupin believes the worst is also over on drug evaluation pressures within the US, the corporate told investors in associate degree interaction when reportage its quarterly earnings.

Indias second-largest drug maker on Tuesday denote an enormous overall loss of Rs 783.5 large integer within the fourth quarter terminated March because of a one-time losses provision on created on sure intangible assets associated with the Gavis acquisition within the US.

Ace capitalist Rakesh Jhunhjhunwala, UN agency holds 1.92% stake in Lupin, was among those that quizzed the management on pricing pressure.

"I will not say that value erosion is gone however i am going to say that days of double-digit value erosion, we have a tendency to hope, area unit behind US, Vinta Gupta, corporate executive of Lupin, same throughout the speak.

Increasing competition and a consolidating client base are symptom profits at drug manufacturers activity to the US, the worlds largest attention market.

So much that several big companies, like Teva and Novartis, area unit even considering swing their generics business on the block.

"Companies have started getting out of portfolios that don't make sense, she told Jhunjhunwala throughout the decision.

Additionally, she same that customers were additionally accommodative of the very fact that the trade has reached a pain purpose and other that balance has to shift.

We are addressing pockets of our portfolio where we have pressures and are working with our channel partners, our customers to see how we can work together to ensure sustainable supply, she added.

The company reported a net profits of Rs 383.6 crore in the fourth quarter.while revenues at Rs 3,952 crore.

A Reuters poll of analysts calculable profits to Rs 323.8 large integer within the fourth quarter, whereas revenues at Rs 3,952 crore.

The company took associate degree upset of 1464.3 crore on Gavis.

Excluding one-time losses provision, the total profit of Lupin stood at Rs 358.6 crore, beyond analyst estimates.

Press to call for Free Trial (022) 3946 4344